Jubilant Pharmova Allots ₹800 Crore Non-Convertible Debentures on Nov 5, 2026
Jubilant Pharmova · Pharmaceuticals & Biotechnology
Key highlights
- Issued 80,000 unsecured, rated, listed, redeemable NCDs of ₹1,00,000 each on private placement
- Tenure of 3 years, coupon rate of 8.50% per annum, listed on BSE Limited
- Allotment date: Nov 5, 2026; Maturity date: Nov 5, 2028; No security or special rights attached
Why it's rated notable: amount is ₹500 crore or more
Original filing
Disclosure Under Regulation 30 And Other Applicable Provisions Of The SEBI (LODR) Regulations, 2015 - Allotment Of Non-Convertible Debentures (Ncds) On A Private Placement Basis-Rs.800 Crores
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Jubilant Pharmova
- Fundraise / allotmentNotableJubilant Pharmova allots ₹800 crore NCDs via private placement on Nov 5, 2026
- Fundraise / allotmentNotableJubilant Pharmova approves issuance of up to ₹800 crore NCDs on private placement
- Order winNotable· Adverse for the businessJubilant Pharmova receives USFDA approval for Line 3 at Spokane facility
- Order winNotable· Adverse for the businessJubilant Pharmova reports USFDA Warning Letter for Montreal contract manufacturing site
Other fundraise / allotment filings this fortnight
- Supreme Engineering allots 14,50,00,000 warrants at ₹2.60 on preferential basis
- Bajaj Finance Limited allots 5.74 crore warrants to Bajaj Finserv on 10 Nov 2026
- Bajaj Finance approves preferential issue of 5.74 crore warrants to Bajaj Finserv
- Chaman Metallics Limited announces H1 FY27 financial results and proposed Rights Issue
- Harmony Capital Services receives BSE approval for preferential issue of shares
- Kuber Udyog: open offer corrigendum, allotments of shares and warrants at ₹23.10
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.